Official Statement from Edward Martin, President and CEO, The Association of Racing Commissioners International (RCI):
RCI continues to rely on the scientific review process at the Racing Medication and Testing Consortium involving key regulatory advisors who are actively involved with the regulation of both Standardbred and Thoroughbred racing as well as the American Association of Equine Practitioners (AAEP). Unfortunately the United States Trotting Association has removed itself from discussions involving those recommendations before they are sent to the RCI.
We understand that there is a debate over Clenbuterol, but note that there are alternatives to treat a Standardbred horse post-race that will better accommodate the Standardbred business model without creating a back door to steroidal-type effects. We have also heard that some are advocating a liberalization of the recommended policy pertaining to corticosteroid use. The AAEP has advised that the use of these drugs in a limited way can be helpful to the horse but the overuse may be detrimental. The policy we have recommended recognizes this.